NCT05003895View on ClinicalTrials.gov

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)

PHASE1RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 8, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Hepatocellular CarcinomaHepatocellular CancerMetastatic Hepatocellular Carcinoma
Interventions
DRUG

Cyclophosphamide

Daily x 3 doses on Day -3, -2, -1 300 mg/m2 IV infusion (200 mg/m2 in Dose Level -1)

BIOLOGICAL

CAR-T cell

Single infusion on Day 0

DRUG

Fludarabine

Daily x 2 doses on Day -2 and -1 30 mg/m2 IV infusion administered following cyclophosphamide

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH